• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Liraglutide unable to improve post-hospitalization course in patients with advanced heart failure

bySusy LamandMichael Milligan
August 5, 2016
in Cardiology, Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This double-blinded, randomized controlled study found that liraglutide, a GLP-1 agonist, did no better than placebo in influencing post-hospitalization clinical stability.

2. There was no significant benefit of the drug in a subgroup of patients with type 2 diabetes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Heart failure is a leading cause of hospitalization, and is attributed to abnormal cardiac metabolism. No current heart failure therapy directly targets these metabolic abnormalities. Thus, it was postulated that agents used to improve glucose metabolism could potentially improve the outcomes of patients with advanced heart failure. This double-blinded, randomized control trial (Functional Impact of GLP-1 for Heart failure Treatment: “FIGHT” study) tested the effects of a glucagon-like peptide 1 agonist, liraglutide, on improving clinical stability in patients with advanced heart failure after hospitalization. The study also analyzed subgroups of patients with and without type 2 diabetes. The results showed that that liraglutide did not improve clinical stability compared with placebo in these patients, nor did it alter left ventricular ejection fraction or N-terminal pro-B-type natriuretic peptide levels. There was no significant difference in deaths between groups. Subgroup analysis of patients with type 2 diabetes, showed equally non-significant results.

This double-blinded randomized control trial had multiple included many patients across several institutions. However, the study was limited by little power in subgroup analyses and a lack of functional metrics, like the 6-minute walk test. In conclusion, this study provides evidence that use of GLP-1 agonists such as liraglutide is not warranted in similar patients with advanced heart failure, nor in those patients with type 2 diabetes for the modulation of cardiac activity.

Click to read the study in JAMA

Relevant Reading: Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance.

RELATED REPORTS

Interatrial shunt device not effective in patients with symptomatic heart failure

Once-a-week cagrilintide is effective for weight management in overweight and obese patients

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

In-Depth [randomized controlled trial]: This multi-center, double blind, placebo controlled study aimed to quantify the effects of liraglutide, a GLP-1 agonist, on clinical stability in patients with advanced heart failure (with and without type 2 diabetes). It included 300 patients with advanced heart failure (AHF) and reduced left ventricular ejection fraction (LVEF). The primary outcome measure was a global rank score in which patients were ranked across three categories: time to death, time to re-hospitalization for AHF, and time-averaged proportional change in N-terminal pro-B natriuretic peptide (NT-proBNP) from baselined to 180 days. Higher values in this global rank score suggested better health and clinical stability. Another primary outcome measure was all-cause mortality.

In total, 154 patients received liraglutide, and 146, placebo. Fifty-nine percent of patients had type-2 diabetes. There was no significant difference in between-group differences for the global rank score (mean rank of 146 in the liraglutide group, 156 in the placebo group; Wilcoxon rank sum p = 0.31). In addition, there was no significant difference in the number of deaths (12% in liraglutide group, 11% in placebo group; hazard ratio 1.10; 95%CI 0.57-2.14; p = 0.78), nor the proportion of re-hospitalization for heart failure (41% in liraglutide group, 34% in placebo group; HR 1.30; 95%CI 0.89-1.88; p = 0.17). The time-averaged proportional change in NT-proBNP levels between groups was 1.52 (SD, 1.71) times baseline levels in the liraglutide group and 1.44 (SD, 1.22) times baseline levels in the placebo group (p = 0.94). Among the patients with type-2 diabetes, there was no statistically significant between-group differences in global rank score (mean rank 85 for liraglutide group and 94 for placebo group; p = 0.27), and the P-value for interaction was 0.60 for treatment based on type 2 diabetes status.

 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: congestive heart failureliraglutide
Previous Post

Microbe-rich environment associated with lower rates of asthma

Next Post

Higher incidence of germline DNA-repair mutations in men with metastatic prostate cancer

RelatedReports

30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
Many new pediatric asthma cases attributable to obesity
Chronic Disease

Once-a-week cagrilintide is effective for weight management in overweight and obese patients

December 21, 2021
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

November 8, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Hemodynamic-guided management of heart failure may reduce hospitalization rates

September 22, 2021
Next Post
Reduced neuronal BRCA1 associated with decreased DNA repair in Alzheimer’s disease [PreClinical]

Higher incidence of germline DNA-repair mutations in men with metastatic prostate cancer

Adalimumab use results in high clinical response rate in hidradenitis suppurativa

Adalimumab use results in high clinical response rate in hidradenitis suppurativa

Oral contraceptive use associated with increased risk of alveolar osteitis

Oral contraceptive use associated with increased risk of alveolar osteitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]
  • #VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
  • Tiotropium bromide safe and effective in treating early childhood wheezing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.